| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 133 | 2019 | 397 | 17.370 |
Why?
|
| Anti-Asthmatic Agents | 32 | 2018 | 71 | 4.670 |
Why?
|
| Bronchodilator Agents | 30 | 2019 | 82 | 3.880 |
Why?
|
| Adrenal Cortex Hormones | 35 | 2019 | 148 | 3.120 |
Why?
|
| Adrenergic beta-Agonists | 20 | 2014 | 50 | 2.470 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 15 | 2019 | 120 | 2.450 |
Why?
|
| Albuterol | 19 | 2018 | 40 | 2.040 |
Why?
|
| Lung | 17 | 2019 | 233 | 1.800 |
Why?
|
| Eosinophils | 12 | 2019 | 48 | 1.780 |
Why?
|
| Humans | 163 | 2019 | 28998 | 1.610 |
Why?
|
| Scopolamine Derivatives | 4 | 2013 | 9 | 1.420 |
Why?
|
| Budesonide | 7 | 2016 | 11 | 1.420 |
Why?
|
| Glucocorticoids | 12 | 2019 | 149 | 1.340 |
Why?
|
| Administration, Inhalation | 35 | 2019 | 92 | 1.330 |
Why?
|
| Receptors, Adrenergic, beta-2 | 11 | 2019 | 36 | 1.300 |
Why?
|
| Sputum | 11 | 2019 | 33 | 1.280 |
Why?
|
| Adult | 88 | 2019 | 8391 | 1.250 |
Why?
|
| Female | 108 | 2019 | 18112 | 1.210 |
Why?
|
| Immunotherapy | 2 | 2017 | 67 | 1.170 |
Why?
|
| Male | 104 | 2019 | 17767 | 1.130 |
Why?
|
| Severity of Illness Index | 26 | 2019 | 863 | 1.110 |
Why?
|
| Middle Aged | 69 | 2019 | 10805 | 1.000 |
Why?
|
| Forced Expiratory Volume | 33 | 2019 | 112 | 1.000 |
Why?
|
| Polymorphism, Single Nucleotide | 24 | 2019 | 1079 | 0.940 |
Why?
|
| Phenotype | 25 | 2018 | 629 | 0.940 |
Why?
|
| Adolescent | 41 | 2019 | 3248 | 0.860 |
Why?
|
| Respiratory Function Tests | 21 | 2018 | 111 | 0.850 |
Why?
|
| Ethanolamines | 5 | 2010 | 16 | 0.840 |
Why?
|
| Polymorphism, Genetic | 6 | 2009 | 196 | 0.810 |
Why?
|
| Double-Blind Method | 22 | 2019 | 501 | 0.810 |
Why?
|
| Bronchial Provocation Tests | 6 | 2011 | 14 | 0.780 |
Why?
|
| Leukotriene Antagonists | 6 | 2016 | 8 | 0.740 |
Why?
|
| Bronchi | 8 | 2018 | 41 | 0.720 |
Why?
|
| Child | 30 | 2018 | 2209 | 0.720 |
Why?
|
| Genetic Predisposition to Disease | 9 | 2019 | 836 | 0.690 |
Why?
|
| Antibodies, Monoclonal | 4 | 2017 | 196 | 0.670 |
Why?
|
| Biological Therapy | 2 | 2017 | 20 | 0.640 |
Why?
|
| Anti-Allergic Agents | 1 | 2017 | 7 | 0.630 |
Why?
|
| Disease Progression | 9 | 2019 | 572 | 0.620 |
Why?
|
| Immune System Diseases | 1 | 2017 | 2 | 0.620 |
Why?
|
| Nasal Polyps | 1 | 2017 | 3 | 0.610 |
Why?
|
| Dyspnea | 3 | 2013 | 30 | 0.600 |
Why?
|
| Neutrophils | 5 | 2017 | 102 | 0.590 |
Why?
|
| Genome-Wide Association Study | 12 | 2019 | 542 | 0.580 |
Why?
|
| Young Adult | 25 | 2019 | 2398 | 0.550 |
Why?
|
| Pharmacogenetics | 7 | 2015 | 35 | 0.550 |
Why?
|
| Drug Therapy, Combination | 10 | 2019 | 273 | 0.550 |
Why?
|
| Acetates | 5 | 2017 | 15 | 0.540 |
Why?
|
| Quinolines | 5 | 2017 | 27 | 0.530 |
Why?
|
| Nebulizers and Vaporizers | 3 | 2017 | 13 | 0.520 |
Why?
|
| Inflammation | 9 | 2019 | 503 | 0.520 |
Why?
|
| Cell Adhesion Molecules | 2 | 2006 | 45 | 0.500 |
Why?
|
| Aged | 29 | 2019 | 9461 | 0.500 |
Why?
|
| Phosphoproteins | 2 | 2006 | 54 | 0.490 |
Why?
|
| Cholinergic Antagonists | 2 | 2010 | 11 | 0.470 |
Why?
|
| Eosinophilia | 3 | 2018 | 16 | 0.460 |
Why?
|
| Internet | 3 | 2017 | 156 | 0.440 |
Why?
|
| Spirometry | 8 | 2019 | 32 | 0.440 |
Why?
|
| Collagen Type III | 2 | 2003 | 13 | 0.440 |
Why?
|
| Leukocyte Count | 8 | 2019 | 55 | 0.440 |
Why?
|
| Respiratory Tract Infections | 3 | 2018 | 41 | 0.440 |
Why?
|
| Cholecalciferol | 3 | 2018 | 21 | 0.430 |
Why?
|
| Cytokines | 4 | 2017 | 243 | 0.420 |
Why?
|
| Fibroblasts | 2 | 2003 | 103 | 0.420 |
Why?
|
| Muscle, Smooth | 4 | 2005 | 73 | 0.410 |
Why?
|
| Epithelial Cells | 2 | 2003 | 138 | 0.410 |
Why?
|
| European Continental Ancestry Group | 7 | 2019 | 1131 | 0.410 |
Why?
|
| Obesity | 6 | 2018 | 1062 | 0.400 |
Why?
|
| Bronchoscopy | 6 | 2017 | 56 | 0.400 |
Why?
|
| Sex Factors | 7 | 2018 | 626 | 0.390 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2010 | 3 | 0.390 |
Why?
|
| Choristoma | 1 | 2010 | 17 | 0.380 |
Why?
|
| Intra-Abdominal Fat | 1 | 2010 | 61 | 0.370 |
Why?
|
| Health Surveys | 2 | 2009 | 191 | 0.370 |
Why?
|
| Treatment Outcome | 19 | 2017 | 3094 | 0.370 |
Why?
|
| Pancreas | 1 | 2010 | 79 | 0.370 |
Why?
|
| Research Design | 3 | 2018 | 285 | 0.360 |
Why?
|
| Occupational Exposure | 2 | 2018 | 224 | 0.360 |
Why?
|
| Immunoglobulin E | 9 | 2019 | 47 | 0.360 |
Why?
|
| Ovarian Neoplasms | 1 | 2010 | 87 | 0.360 |
Why?
|
| Treatment Failure | 8 | 2018 | 159 | 0.350 |
Why?
|
| Alendronate | 2 | 2019 | 12 | 0.350 |
Why?
|
| Receptors, Adrenergic, beta | 2 | 2006 | 13 | 0.350 |
Why?
|
| Genetic Association Studies | 1 | 2009 | 148 | 0.350 |
Why?
|
| Chlorofluorocarbons | 1 | 2009 | 1 | 0.350 |
Why?
|
| Aerosol Propellants | 1 | 2009 | 2 | 0.350 |
Why?
|
| Hydrocarbons, Fluorinated | 1 | 2009 | 4 | 0.340 |
Why?
|
| Bronchial Hyperreactivity | 6 | 2015 | 22 | 0.340 |
Why?
|
| United States | 15 | 2019 | 3604 | 0.340 |
Why?
|
| Anti-Inflammatory Agents | 4 | 2015 | 90 | 0.340 |
Why?
|
| Patient Acceptance of Health Care | 4 | 2019 | 154 | 0.330 |
Why?
|
| Microfilament Proteins | 2 | 2006 | 33 | 0.330 |
Why?
|
| Nitric Oxide | 8 | 2017 | 116 | 0.320 |
Why?
|
| Inflammation Mediators | 2 | 2010 | 101 | 0.320 |
Why?
|
| Case-Control Studies | 10 | 2019 | 855 | 0.310 |
Why?
|
| Drug Resistance | 2 | 2017 | 36 | 0.300 |
Why?
|
| Bronchoalveolar Lavage Fluid | 4 | 2017 | 67 | 0.300 |
Why?
|
| Hypersensitivity | 1 | 2007 | 25 | 0.300 |
Why?
|
| Beclomethasone | 6 | 2015 | 8 | 0.300 |
Why?
|
| Peak Expiratory Flow Rate | 9 | 2018 | 15 | 0.300 |
Why?
|
| Cross-Over Studies | 5 | 2019 | 93 | 0.290 |
Why?
|
| Patient Education as Topic | 1 | 2009 | 251 | 0.290 |
Why?
|
| Interleukin-13 | 6 | 2012 | 33 | 0.290 |
Why?
|
| Clinical Trials as Topic | 6 | 2013 | 298 | 0.290 |
Why?
|
| Hypersensitivity, Immediate | 2 | 2016 | 9 | 0.290 |
Why?
|
| Vitamin D Deficiency | 3 | 2018 | 89 | 0.290 |
Why?
|
| Risk Assessment | 7 | 2019 | 1300 | 0.290 |
Why?
|
| Th2 Cells | 4 | 2016 | 14 | 0.280 |
Why?
|
| Th1 Cells | 3 | 2013 | 18 | 0.280 |
Why?
|
| Animals | 8 | 2017 | 7296 | 0.270 |
Why?
|
| Dietary Supplements | 2 | 2018 | 170 | 0.270 |
Why?
|
| Prospective Studies | 8 | 2019 | 2010 | 0.270 |
Why?
|
| Genetic Loci | 3 | 2019 | 147 | 0.270 |
Why?
|
| Skin | 2 | 2017 | 203 | 0.270 |
Why?
|
| Arginase | 3 | 2010 | 8 | 0.260 |
Why?
|
| Pregnadienediols | 2 | 2015 | 2 | 0.260 |
Why?
|
| Paranasal Sinuses | 2 | 2015 | 6 | 0.260 |
Why?
|
| Allergy and Immunology | 1 | 2004 | 3 | 0.260 |
Why?
|
| Genotype | 10 | 2016 | 735 | 0.260 |
Why?
|
| Hispanic Americans | 2 | 2016 | 904 | 0.250 |
Why?
|
| Risk Factors | 9 | 2018 | 3509 | 0.250 |
Why?
|
| Prognosis | 5 | 2018 | 1362 | 0.240 |
Why?
|
| Postural Balance | 1 | 2016 | 160 | 0.240 |
Why?
|
| Pesticides | 1 | 2016 | 189 | 0.230 |
Why?
|
| Transforming Growth Factors | 1 | 2003 | 3 | 0.230 |
Why?
|
| Antigenic Modulation | 1 | 2003 | 2 | 0.230 |
Why?
|
| Anti-Bacterial Agents | 3 | 2018 | 284 | 0.230 |
Why?
|
| Actins | 1 | 2003 | 52 | 0.230 |
Why?
|
| Airway Obstruction | 4 | 2013 | 31 | 0.230 |
Why?
|
| Signal Transduction | 5 | 2018 | 666 | 0.220 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 235 | 0.220 |
Why?
|
| Vital Capacity | 5 | 2018 | 44 | 0.220 |
Why?
|
| Transients and Migrants | 1 | 2016 | 281 | 0.220 |
Why?
|
| Haplotypes | 4 | 2010 | 220 | 0.220 |
Why?
|
| Biopsy | 4 | 2017 | 241 | 0.220 |
Why?
|
| Practice Guidelines as Topic | 4 | 2017 | 373 | 0.220 |
Why?
|
| Recurrence | 3 | 2017 | 235 | 0.210 |
Why?
|
| Myofibrils | 1 | 2002 | 10 | 0.210 |
Why?
|
| Cohort Studies | 9 | 2019 | 1674 | 0.210 |
Why?
|
| Breath Tests | 5 | 2017 | 17 | 0.210 |
Why?
|
| Receptors, Glucocorticoid | 3 | 2011 | 8 | 0.210 |
Why?
|
| Age of Onset | 5 | 2012 | 95 | 0.200 |
Why?
|
| African Americans | 6 | 2019 | 1373 | 0.200 |
Why?
|
| Disease Management | 3 | 2017 | 114 | 0.200 |
Why?
|
| Arginine | 2 | 2012 | 17 | 0.200 |
Why?
|
| Comorbidity | 4 | 2017 | 539 | 0.200 |
Why?
|
| Aging | 3 | 2017 | 880 | 0.190 |
Why?
|
| Age Factors | 8 | 2017 | 1105 | 0.190 |
Why?
|
| Amino Acids | 2 | 2019 | 41 | 0.190 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2019 | 6 | 0.180 |
Why?
|
| Child, Preschool | 7 | 2019 | 1164 | 0.180 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2019 | 9 | 0.180 |
Why?
|
| Prevalence | 3 | 2007 | 892 | 0.180 |
Why?
|
| Respiratory Sounds | 1 | 2019 | 10 | 0.170 |
Why?
|
| Muscarinic Antagonists | 1 | 2019 | 15 | 0.170 |
Why?
|
| Emergency Service, Hospital | 2 | 2019 | 429 | 0.170 |
Why?
|
| T-Lymphocytes | 2 | 2011 | 114 | 0.170 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2010 | 22 | 0.170 |
Why?
|
| Androstadienes | 4 | 2010 | 17 | 0.170 |
Why?
|
| Corynebacterium | 1 | 2018 | 1 | 0.170 |
Why?
|
| Smoking | 2 | 2019 | 427 | 0.170 |
Why?
|
| Moraxella | 1 | 2018 | 3 | 0.170 |
Why?
|
| Aspirin | 1 | 2018 | 61 | 0.170 |
Why?
|
| Sleep | 1 | 2019 | 84 | 0.170 |
Why?
|
| Cluster Analysis | 3 | 2013 | 128 | 0.160 |
Why?
|
| Preoperative Care | 1 | 2019 | 110 | 0.160 |
Why?
|
| Patient Care Team | 1 | 2019 | 124 | 0.160 |
Why?
|
| Guideline Adherence | 1 | 2019 | 110 | 0.160 |
Why?
|
| Multivariate Analysis | 6 | 2018 | 636 | 0.160 |
Why?
|
| Hydroxyurea | 1 | 2018 | 3 | 0.160 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2018 | 56 | 0.160 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2018 | 28 | 0.160 |
Why?
|
| Interleukin-4 | 2 | 2012 | 20 | 0.160 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2017 | 15 | 0.160 |
Why?
|
| Indoleacetic Acids | 1 | 2017 | 2 | 0.160 |
Why?
|
| Laboratories | 1 | 2017 | 13 | 0.160 |
Why?
|
| Shewanella putrefaciens | 1 | 2017 | 1 | 0.160 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2018 | 462 | 0.160 |
Why?
|
| Body Mass Index | 6 | 2018 | 862 | 0.160 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2017 | 13 | 0.160 |
Why?
|
| Soft Tissue Infections | 1 | 2017 | 10 | 0.160 |
Why?
|
| Pathology | 1 | 2017 | 20 | 0.160 |
Why?
|
| Pyridines | 1 | 2017 | 78 | 0.150 |
Why?
|
| Autoimmunity | 1 | 2017 | 26 | 0.150 |
Why?
|
| Hand | 1 | 2017 | 63 | 0.150 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2017 | 26 | 0.150 |
Why?
|
| Membrane Glycoproteins | 2 | 2011 | 97 | 0.150 |
Why?
|
| Ibuprofen | 1 | 2016 | 4 | 0.150 |
Why?
|
| Emphysema | 1 | 2016 | 5 | 0.150 |
Why?
|
| Blood Proteins | 1 | 2016 | 18 | 0.150 |
Why?
|
| Delayed-Action Preparations | 1 | 2016 | 35 | 0.150 |
Why?
|
| Self Care | 1 | 2017 | 136 | 0.140 |
Why?
|
| Acetaminophen | 1 | 2016 | 18 | 0.140 |
Why?
|
| Patient Readmission | 1 | 2017 | 105 | 0.140 |
Why?
|
| Fluocinolone Acetonide | 2 | 2009 | 7 | 0.140 |
Why?
|
| Biomedical Research | 3 | 2012 | 153 | 0.140 |
Why?
|
| Antibodies, Anti-Idiotypic | 2 | 2006 | 7 | 0.140 |
Why?
|
| Medicare | 1 | 2017 | 185 | 0.140 |
Why?
|
| Azithromycin | 1 | 2015 | 14 | 0.140 |
Why?
|
| Respiratory System | 2 | 2007 | 12 | 0.140 |
Why?
|
| Skin Diseases | 1 | 2017 | 138 | 0.140 |
Why?
|
| Aged, 80 and over | 7 | 2018 | 3712 | 0.130 |
Why?
|
| Secondary Prevention | 1 | 2015 | 59 | 0.130 |
Why?
|
| African Continental Ancestry Group | 1 | 2017 | 350 | 0.130 |
Why?
|
| Linkage Disequilibrium | 6 | 2012 | 192 | 0.130 |
Why?
|
| Outpatients | 1 | 2015 | 49 | 0.130 |
Why?
|
| Bacteria | 2 | 2016 | 45 | 0.130 |
Why?
|
| Peptide Fragments | 1 | 2018 | 420 | 0.130 |
Why?
|
| Predictive Value of Tests | 2 | 2014 | 784 | 0.130 |
Why?
|
| Palliative Care | 1 | 2015 | 47 | 0.130 |
Why?
|
| Odds Ratio | 5 | 2015 | 446 | 0.130 |
Why?
|
| Reproducibility of Results | 3 | 2014 | 724 | 0.130 |
Why?
|
| Interleukin-1 | 2 | 2005 | 33 | 0.130 |
Why?
|
| Pregnenediones | 1 | 2014 | 2 | 0.130 |
Why?
|
| Granulocytes | 2 | 2013 | 12 | 0.120 |
Why?
|
| Uncertainty | 1 | 2014 | 12 | 0.120 |
Why?
|
| Diagnostic Techniques, Respiratory System | 1 | 2014 | 1 | 0.120 |
Why?
|
| Clarithromycin | 2 | 2010 | 2 | 0.120 |
Why?
|
| Edetic Acid | 1 | 2014 | 8 | 0.120 |
Why?
|
| Serum | 1 | 2014 | 20 | 0.120 |
Why?
|
| Plasma | 1 | 2014 | 15 | 0.120 |
Why?
|
| Zinc Fingers | 1 | 2013 | 8 | 0.120 |
Why?
|
| Patient Preference | 1 | 2014 | 38 | 0.120 |
Why?
|
| Brain Death | 1 | 2014 | 27 | 0.120 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2007 | 200 | 0.120 |
Why?
|
| Drug Administration Schedule | 6 | 2015 | 246 | 0.120 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2014 | 35 | 0.120 |
Why?
|
| Vitamins | 1 | 2014 | 58 | 0.120 |
Why?
|
| Repressor Proteins | 1 | 2013 | 53 | 0.120 |
Why?
|
| Gene Expression | 2 | 2012 | 332 | 0.120 |
Why?
|
| Multifactorial Inheritance | 1 | 2013 | 19 | 0.120 |
Why?
|
| Pulmonary Diffusing Capacity | 1 | 2013 | 2 | 0.120 |
Why?
|
| Kv Channel-Interacting Proteins | 1 | 2013 | 3 | 0.110 |
Why?
|
| Interferon-gamma | 4 | 2010 | 51 | 0.110 |
Why?
|
| Liver Transplantation | 1 | 2014 | 111 | 0.110 |
Why?
|
| Receptors, Tumor Necrosis Factor | 2 | 2003 | 45 | 0.110 |
Why?
|
| Interleukin-4 Receptor alpha Subunit | 1 | 2012 | 6 | 0.110 |
Why?
|
| Macrolides | 1 | 2012 | 8 | 0.110 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2012 | 13 | 0.110 |
Why?
|
| Carrier Proteins | 2 | 2011 | 131 | 0.110 |
Why?
|
| Dinoprostone | 3 | 2006 | 37 | 0.100 |
Why?
|
| RNA, Ribosomal, 16S | 3 | 2018 | 13 | 0.100 |
Why?
|
| Chronic Disease | 3 | 2014 | 369 | 0.100 |
Why?
|
| Metered Dose Inhalers | 2 | 2008 | 5 | 0.100 |
Why?
|
| Proteins | 1 | 2012 | 140 | 0.100 |
Why?
|
| Acute Disease | 3 | 2018 | 239 | 0.100 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2011 | 36 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2018 | 641 | 0.100 |
Why?
|
| Retrospective Studies | 6 | 2017 | 3100 | 0.100 |
Why?
|
| Liver | 1 | 2014 | 464 | 0.100 |
Why?
|
| Incidental Findings | 1 | 2010 | 26 | 0.100 |
Why?
|
| Time Factors | 3 | 2011 | 1997 | 0.090 |
Why?
|
| Preferred Provider Organizations | 1 | 2010 | 2 | 0.090 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2010 | 49 | 0.090 |
Why?
|
| Cross-Sectional Studies | 4 | 2018 | 1353 | 0.090 |
Why?
|
| Health Maintenance Organizations | 1 | 2010 | 13 | 0.090 |
Why?
|
| Insurance Claim Review | 1 | 2010 | 27 | 0.090 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2010 | 10 | 0.090 |
Why?
|
| HLA-DQ Antigens | 1 | 2010 | 9 | 0.090 |
Why?
|
| HLA-DR Antigens | 1 | 2010 | 8 | 0.090 |
Why?
|
| DNA Repair Enzymes | 1 | 2010 | 16 | 0.090 |
Why?
|
| Drug Dosage Calculations | 1 | 2010 | 7 | 0.090 |
Why?
|
| Lymphatic Metastasis | 1 | 2010 | 156 | 0.090 |
Why?
|
| Lymph Node Excision | 1 | 2010 | 89 | 0.090 |
Why?
|
| Logistic Models | 4 | 2015 | 725 | 0.090 |
Why?
|
| Drug Synergism | 1 | 2010 | 67 | 0.090 |
Why?
|
| Allergens | 2 | 2016 | 16 | 0.090 |
Why?
|
| Superoxide Dismutase | 2 | 2011 | 47 | 0.090 |
Why?
|
| Sample Size | 1 | 2009 | 37 | 0.090 |
Why?
|
| Influenza Vaccines | 1 | 2010 | 78 | 0.090 |
Why?
|
| Lymphocyte Activation | 2 | 2010 | 80 | 0.090 |
Why?
|
| DNA-Binding Proteins | 1 | 2010 | 142 | 0.090 |
Why?
|
| Influenza, Human | 1 | 2010 | 122 | 0.090 |
Why?
|
| Patients | 1 | 2009 | 46 | 0.090 |
Why?
|
| Heat-Shock Proteins | 1 | 2009 | 28 | 0.090 |
Why?
|
| Infant | 3 | 2016 | 967 | 0.080 |
Why?
|
| ROC Curve | 3 | 2017 | 148 | 0.080 |
Why?
|
| Diagnosis, Differential | 1 | 2010 | 493 | 0.080 |
Why?
|
| Cells, Cultured | 5 | 2010 | 799 | 0.080 |
Why?
|
| Safety | 1 | 2008 | 72 | 0.080 |
Why?
|
| Receptors, Leukotriene | 1 | 2008 | 4 | 0.080 |
Why?
|
| Linear Models | 3 | 2018 | 425 | 0.080 |
Why?
|
| Receptors, Muscarinic | 1 | 2008 | 10 | 0.080 |
Why?
|
| Bronchoconstriction | 1 | 2007 | 2 | 0.080 |
Why?
|
| Neutrophil Activation | 1 | 2007 | 5 | 0.080 |
Why?
|
| Airway Resistance | 1 | 2007 | 5 | 0.080 |
Why?
|
| North Carolina | 2 | 2017 | 1422 | 0.080 |
Why?
|
| Attitude to Health | 1 | 2009 | 147 | 0.080 |
Why?
|
| Amino Acid Substitution | 1 | 2007 | 40 | 0.080 |
Why?
|
| Apoptosis | 3 | 2006 | 337 | 0.080 |
Why?
|
| Physician-Patient Relations | 1 | 2009 | 169 | 0.080 |
Why?
|
| Rhinitis | 1 | 2007 | 11 | 0.080 |
Why?
|
| Sinusitis | 1 | 2007 | 17 | 0.070 |
Why?
|
| Phospholipases A | 2 | 2005 | 28 | 0.070 |
Why?
|
| Isoproterenol | 1 | 2006 | 18 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2010 | 152 | 0.070 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2007 | 25 | 0.070 |
Why?
|
| Quantitative Trait Loci | 2 | 2018 | 140 | 0.070 |
Why?
|
| Ocular Hypertension | 1 | 2006 | 6 | 0.070 |
Why?
|
| Pituitary-Adrenal System | 1 | 2006 | 24 | 0.070 |
Why?
|
| Cataract | 1 | 2006 | 5 | 0.070 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2006 | 34 | 0.070 |
Why?
|
| Risk | 2 | 2018 | 289 | 0.070 |
Why?
|
| Glaucoma | 1 | 2006 | 11 | 0.070 |
Why?
|
| Longitudinal Studies | 2 | 2019 | 708 | 0.070 |
Why?
|
| Patient Selection | 1 | 2008 | 257 | 0.070 |
Why?
|
| Bronchoalveolar Lavage | 2 | 2005 | 15 | 0.070 |
Why?
|
| Cost of Illness | 1 | 2006 | 63 | 0.070 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2005 | 9 | 0.070 |
Why?
|
| CpG Islands | 1 | 2005 | 44 | 0.070 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2005 | 17 | 0.070 |
Why?
|
| Respiratory Mucosa | 1 | 2005 | 10 | 0.070 |
Why?
|
| MAP Kinase Signaling System | 1 | 2005 | 57 | 0.070 |
Why?
|
| Dermatitis, Atopic | 1 | 2007 | 86 | 0.070 |
Why?
|
| Tosyl Compounds | 1 | 2005 | 4 | 0.070 |
Why?
|
| Pregnancy Complications | 1 | 2006 | 78 | 0.070 |
Why?
|
| Phosphorylation | 1 | 2006 | 225 | 0.070 |
Why?
|
| Respiratory Physiological Phenomena | 1 | 2005 | 6 | 0.070 |
Why?
|
| Trachea | 1 | 2005 | 55 | 0.070 |
Why?
|
| Rhinitis, Allergic, Perennial | 1 | 2005 | 7 | 0.070 |
Why?
|
| Lung Diseases | 1 | 2005 | 44 | 0.070 |
Why?
|
| Regression Analysis | 2 | 2017 | 272 | 0.070 |
Why?
|
| Neovascularization, Physiologic | 1 | 2005 | 106 | 0.070 |
Why?
|
| Bone Density | 1 | 2006 | 182 | 0.060 |
Why?
|
| Interleukin-2 | 3 | 2010 | 33 | 0.060 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 2105 | 0.060 |
Why?
|
| Ethnic Groups | 1 | 2007 | 440 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2019 | 871 | 0.060 |
Why?
|
| Interleukin-5 | 1 | 2003 | 7 | 0.060 |
Why?
|
| Pregnancy | 1 | 2006 | 807 | 0.060 |
Why?
|
| Leukotriene D4 | 1 | 2003 | 2 | 0.060 |
Why?
|
| Endpoint Determination | 1 | 2003 | 19 | 0.060 |
Why?
|
| Patient Compliance | 2 | 2019 | 208 | 0.060 |
Why?
|
| Killer Cells, Natural | 1 | 2002 | 24 | 0.050 |
Why?
|
| Methacholine Chloride | 3 | 2007 | 5 | 0.050 |
Why?
|
| Algorithms | 2 | 2017 | 461 | 0.050 |
Why?
|
| Blotting, Western | 1 | 2002 | 281 | 0.050 |
Why?
|
| Membrane Proteins | 1 | 2002 | 256 | 0.050 |
Why?
|
| Cell Culture Techniques | 1 | 2002 | 165 | 0.050 |
Why?
|
| TATA Box Binding Protein-Like Proteins | 1 | 2019 | 1 | 0.050 |
Why?
|
| Mucin-5B | 1 | 2019 | 3 | 0.050 |
Why?
|
| beta Karyopherins | 1 | 2019 | 7 | 0.050 |
Why?
|
| Administration, Oral | 2 | 2014 | 169 | 0.050 |
Why?
|
| Base Sequence | 2 | 2013 | 240 | 0.050 |
Why?
|
| Placebos | 2 | 2012 | 61 | 0.050 |
Why?
|
| Isoleucine | 1 | 2019 | 8 | 0.050 |
Why?
|
| Tryptophan | 1 | 2019 | 5 | 0.050 |
Why?
|
| Valine | 1 | 2019 | 17 | 0.040 |
Why?
|
| Leucine | 1 | 2019 | 24 | 0.040 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2019 | 59 | 0.040 |
Why?
|
| Metabolomics | 1 | 2019 | 45 | 0.040 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2019 | 8 | 0.040 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2019 | 14 | 0.040 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2019 | 17 | 0.040 |
Why?
|
| Fibrinogen | 1 | 2019 | 42 | 0.040 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2019 | 46 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 1 | 2019 | 212 | 0.040 |
Why?
|
| Skin Tests | 2 | 2010 | 15 | 0.040 |
Why?
|
| Flow Cytometry | 2 | 2010 | 171 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 2 | 2010 | 172 | 0.040 |
Why?
|
| Incidence | 2 | 2016 | 1105 | 0.040 |
Why?
|
| Vitamin D-Binding Protein | 1 | 2018 | 10 | 0.040 |
Why?
|
| Nose | 1 | 2018 | 12 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2019 | 262 | 0.040 |
Why?
|
| Puberty | 1 | 2018 | 8 | 0.040 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2018 | 82 | 0.040 |
Why?
|
| Growth | 1 | 2018 | 7 | 0.040 |
Why?
|
| Mouth Mucosa | 1 | 2018 | 29 | 0.040 |
Why?
|
| Leukotrienes | 1 | 2018 | 4 | 0.040 |
Why?
|
| Current Procedural Terminology | 1 | 2017 | 4 | 0.040 |
Why?
|
| C-Reactive Protein | 1 | 2019 | 229 | 0.040 |
Why?
|
| Inspiratory Capacity | 1 | 2017 | 2 | 0.040 |
Why?
|
| Immunocompetence | 1 | 2017 | 12 | 0.040 |
Why?
|
| Patient Care | 1 | 2017 | 33 | 0.040 |
Why?
|
| Hand Injuries | 1 | 2017 | 24 | 0.040 |
Why?
|
| Quality of Life | 2 | 2014 | 814 | 0.040 |
Why?
|
| Foreign Bodies | 1 | 2017 | 29 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2019 | 144 | 0.040 |
Why?
|
| Specialization | 1 | 2017 | 30 | 0.040 |
Why?
|
| Workflow | 1 | 2017 | 20 | 0.040 |
Why?
|
| Prednisolone | 1 | 2017 | 10 | 0.040 |
Why?
|
| Reference Values | 2 | 2011 | 224 | 0.040 |
Why?
|
| RNA, Bacterial | 1 | 2016 | 4 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2017 | 53 | 0.040 |
Why?
|
| Bronchoconstrictor Agents | 2 | 2007 | 3 | 0.040 |
Why?
|
| Cell Line | 1 | 2018 | 449 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2017 | 185 | 0.040 |
Why?
|
| ABO Blood-Group System | 1 | 2016 | 19 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 292 | 0.040 |
Why?
|
| Fever | 1 | 2016 | 56 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2017 | 385 | 0.040 |
Why?
|
| Forced Expiratory Flow Rates | 1 | 2015 | 3 | 0.040 |
Why?
|
| RNA, Messenger | 1 | 2018 | 514 | 0.030 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2015 | 38 | 0.030 |
Why?
|
| Accidental Falls | 1 | 2017 | 204 | 0.030 |
Why?
|
| Nutrition Surveys | 1 | 2016 | 133 | 0.030 |
Why?
|
| Phospholipases A2 | 2 | 2005 | 22 | 0.030 |
Why?
|
| Administration, Intranasal | 1 | 2014 | 30 | 0.030 |
Why?
|
| Triamcinolone | 2 | 2005 | 11 | 0.030 |
Why?
|
| Ionophores | 2 | 2005 | 5 | 0.030 |
Why?
|
| Calcimycin | 2 | 2005 | 7 | 0.030 |
Why?
|
| Tetradecanoylphorbol Acetate | 2 | 2005 | 12 | 0.030 |
Why?
|
| F-Box Proteins | 1 | 2014 | 4 | 0.030 |
Why?
|
| Combined Modality Therapy | 2 | 2006 | 523 | 0.030 |
Why?
|
| New Jersey | 1 | 2014 | 10 | 0.030 |
Why?
|
| Protease Inhibitors | 1 | 2014 | 14 | 0.030 |
Why?
|
| Cell Survival | 2 | 2006 | 272 | 0.030 |
Why?
|
| Pain | 1 | 2016 | 282 | 0.030 |
Why?
|
| Observer Variation | 1 | 2014 | 96 | 0.030 |
Why?
|
| Liver Cirrhosis | 1 | 2014 | 75 | 0.030 |
Why?
|
| Interferon Regulatory Factor-2 | 1 | 2013 | 5 | 0.030 |
Why?
|
| STAT4 Transcription Factor | 1 | 2013 | 16 | 0.030 |
Why?
|
| Fatty Liver | 1 | 2014 | 66 | 0.030 |
Why?
|
| Interleukin-12 | 1 | 2013 | 26 | 0.030 |
Why?
|
| Single-Blind Method | 2 | 2004 | 165 | 0.030 |
Why?
|
| Nuclear Pore | 1 | 2012 | 3 | 0.030 |
Why?
|
| Prednisone | 1 | 2012 | 43 | 0.030 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2012 | 5 | 0.030 |
Why?
|
| Tissue Donors | 1 | 2014 | 167 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2012 | 25 | 0.030 |
Why?
|
| Homozygote | 1 | 2012 | 57 | 0.030 |
Why?
|
| Airway Remodeling | 1 | 2011 | 5 | 0.030 |
Why?
|
| Hydrocortisone | 2 | 2002 | 61 | 0.030 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2012 | 74 | 0.030 |
Why?
|
| Total Lung Capacity | 1 | 2011 | 1 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2011 | 10 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2011 | 8 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2011 | 9 | 0.030 |
Why?
|
| Alleles | 1 | 2012 | 251 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2011 | 95 | 0.030 |
Why?
|
| Thrombospondins | 1 | 2011 | 7 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2012 | 224 | 0.030 |
Why?
|
| Leptin | 1 | 2011 | 66 | 0.030 |
Why?
|
| Asian Continental Ancestry Group | 1 | 2011 | 110 | 0.020 |
Why?
|
| Receptors, Notch | 1 | 2011 | 16 | 0.020 |
Why?
|
| Exhalation | 1 | 2010 | 4 | 0.020 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2010 | 28 | 0.020 |
Why?
|
| Chlamydophila pneumoniae | 1 | 2010 | 4 | 0.020 |
Why?
|
| Phylogeny | 1 | 2010 | 58 | 0.020 |
Why?
|
| Mycoplasma pneumoniae | 1 | 2010 | 5 | 0.020 |
Why?
|
| Hospitalization | 1 | 2014 | 417 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2010 | 66 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 2011 | 72 | 0.020 |
Why?
|
| Lymphocyte Count | 1 | 2010 | 23 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2011 | 90 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2010 | 49 | 0.020 |
Why?
|
| Environmental Exposure | 1 | 2011 | 86 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 155 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2010 | 16 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 531 | 0.020 |
Why?
|
| Discriminant Analysis | 1 | 2009 | 18 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2010 | 248 | 0.020 |
Why?
|
| Vaccination | 1 | 2010 | 123 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2010 | 469 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2009 | 225 | 0.020 |
Why?
|
| Biological Availability | 1 | 2008 | 21 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2009 | 160 | 0.020 |
Why?
|
| London | 1 | 2007 | 3 | 0.020 |
Why?
|
| Lung Volume Measurements | 1 | 2007 | 5 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2007 | 82 | 0.020 |
Why?
|
| Motor Activity | 1 | 2010 | 310 | 0.020 |
Why?
|
| Patient Satisfaction | 1 | 2009 | 222 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2007 | 20 | 0.020 |
Why?
|
| DNA Primers | 1 | 2007 | 87 | 0.020 |
Why?
|
| Cyclic AMP-Dependent Protein Kinase Type II | 1 | 2006 | 1 | 0.020 |
Why?
|
| Hypertension | 1 | 2014 | 899 | 0.020 |
Why?
|
| Mice | 1 | 2013 | 2368 | 0.020 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2006 | 18 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2006 | 138 | 0.020 |
Why?
|
| Microsomes | 1 | 2005 | 14 | 0.020 |
Why?
|
| Cytosol | 1 | 2005 | 25 | 0.020 |
Why?
|
| Cyclooxygenase 1 | 1 | 2005 | 23 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2005 | 37 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2005 | 44 | 0.020 |
Why?
|
| Protein Kinases | 1 | 2005 | 28 | 0.020 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2005 | 32 | 0.020 |
Why?
|
| Carcinogens | 1 | 2005 | 34 | 0.020 |
Why?
|
| Oxytocics | 1 | 2005 | 11 | 0.020 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2005 | 36 | 0.020 |
Why?
|
| Protein Kinase C | 1 | 2005 | 37 | 0.020 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2006 | 145 | 0.020 |
Why?
|
| Cyclooxygenase 2 | 1 | 2005 | 50 | 0.020 |
Why?
|
| Glutathione Peroxidase | 1 | 2005 | 8 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2005 | 75 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2005 | 100 | 0.020 |
Why?
|
| Cell Count | 1 | 2005 | 50 | 0.020 |
Why?
|
| Glutathione | 1 | 2005 | 37 | 0.020 |
Why?
|
| Delivery of Health Care | 1 | 2007 | 142 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2006 | 251 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2005 | 162 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2005 | 91 | 0.020 |
Why?
|
| Periodicals as Topic | 1 | 2005 | 95 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2005 | 223 | 0.010 |
Why?
|
| BH3 Interacting Domain Death Agonist Protein | 1 | 2003 | 2 | 0.010 |
Why?
|
| Caspase 9 | 1 | 2003 | 7 | 0.010 |
Why?
|
| Caspase 8 | 1 | 2003 | 9 | 0.010 |
Why?
|
| Caspases | 1 | 2003 | 31 | 0.010 |
Why?
|
| Tumor Necrosis Factor Decoy Receptors | 1 | 2002 | 3 | 0.010 |
Why?
|
| Immune Sera | 1 | 2002 | 9 | 0.010 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2002 | 6 | 0.010 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2002 | 10 | 0.010 |
Why?
|
| Solubility | 1 | 2002 | 38 | 0.010 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2002 | 33 | 0.010 |
Why?
|
| Survival Rate | 1 | 2005 | 795 | 0.010 |
Why?
|
| Lymphocyte Subsets | 1 | 2002 | 7 | 0.010 |
Why?
|
| Probability | 1 | 2002 | 150 | 0.010 |
Why?
|
| Cell Division | 1 | 2002 | 97 | 0.010 |
Why?
|
| Cell Movement | 1 | 2002 | 161 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2002 | 595 | 0.010 |
Why?
|